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Mucormycosis is difficult to diagnose. Samples from suspected cases often fail to growMucorales inmicrobiologic
cultures. We identified all hematologic malignancy and stem cell transplant patients diagnosed with proven
mucormycosis between 2001 and 2009 at Brigham and Women’s Hospital/Dana-Farber Cancer Institute. Semin-
ested PCR targeting Mucorales 18S ribosomal DNA and sequencing were performed on formalin-fixed paraffin-
embedded tissue samples. Of 29 cases of mucormycosis, 27 had tissue samples available for PCR and sequencing.
Mucorales PCR was positive in 22. Among 12 culture-positive cases, 10 were PCR positive and sequencing was
concordant with culture results to the genus level in 9. Among 15 culture-negative cases, PCR was positive and
sequencing allowed genus identification in 12. Mucorales PCR is useful for confirmation of the diagnosis of
mucormycosis and for further characterization of the infection in cases where cultures are negative.
The reported incidence of mucormycosis (previously re-
ferred to as zygomycosis) (6) has been increasing in the last 2
decades, particularly among immunocompromised patients (3,
11, 12). In a recent study of invasive fungal disease in hema-
topoietic stem cell transplant (HSCT) recipients, mucormyco-
sis was the third most common infection, after candidiasis and
aspergillosis (8).
Despite its increasing frequency, mucormycosis remains dif-
ficult to diagnose. Radiographically and clinically, mucormy-
cosis is often indistinguishable from other common invasive
mold infections, such as aspergillosis. Histopathology is the
“gold standard” for diagnosis. However, histopathologic iden-
tification of Mucorales in tissue specimens requires significant
pathological expertise and does not allow species identifica-
tion. Organisms in tissue specimens with histopathologically
identified mucormycosis often fail to grow in fungal cultures.
In a review of 929 cases of mucormycosis reported between
1940 and 2003, only 50% were culture positive (11).
The inability to confirm histopathologically diagnosed mu-
cormycosis and determine the species has important treatment
implications. In comparison to Aspergillus species, which are
typically susceptible to voriconazole, amphotericin B, and echi-
nocandins, Mucorales are usually susceptible only to ampho-
tericin B and less frequently to posaconazole (1). Furthermore,
there is significant variability in susceptibility by genus; in a
study of 217 clinical isolates of Mucorales, 100% of Lich-
theimia spp. (syn. Absidia pro parte), Rhizomucor spp., and
Rhizopus spp. were susceptible to amphotericin B, while only
63% of Cunninghamella sp. isolates were susceptible (1). Thus,
novel techniques to confirm the diagnosis of mucormycosis in
tissue and identify the infecting species are needed.
Detection of fungal DNA in tissue samples by PCR is a
novel non-culture-based method that may allow improved di-
agnosis of mucormycosis (2, 4, 7, 9, 10). In particular, PCR
with sequencing of the 18S ribosomal DNA of Mucorales in
order to diagnose mucormycosis and identify the infecting spe-
cies in paraffin-embedded tissue samples in clinical cases of
invasive fungal infection has been described (2, 9, 10). We
assessed the performance of Mucorales 18S ribosomal DNA
PCR and sequencing in a retrospective cohort of patients
treated for hematological malignancies with histopathologi-
cally proven mucormycosis.
(This work was presented in abstract form at the 50th Inter-
science Conference on Antimicrobial Agents and Chemother-
apy, Boston, MA, 12 September 2010, abstr. M-414.)
MATERIALS AND METHODS
Patients and definitions. All adult patients with hematologic malignancy and
HSCT recipients at Brigham and Women’s Hospital/Dana-Farber Cancer Insti-
tute (BWH/DFCI) who developed proven mucormycosis between 1 January 2001
and 31 December 2009 were identified. Computerized medical records were
reviewed for underlying hematologic diagnosis, stem cell transplant status, mi-
crobiologic results, pathological results (from tissue aspirates, biopsy specimens,
or autopsy specimens), and radiographic results. This study was approved by the
Partners Healthcare Human Research Committee.
The routine clinical approach to patients with suspected invasive mold infec-
tion in whom serum fungal antigens (galactomannan beginning in 2003 and
133--D-glucan beginning in 2004) do not suggest a diagnosis at BWH/DFCI
includes surgical biopsy or computed tomography-guided collection of a fine-needle
aspirate of the affected area. Proven mucormycosis was defined by use of the
European Organization for Research and Treatment of Cancer/Mycosis Study
Group criteria on the basis of pathological assessment of tissue samples at the time
that the sample was collected (5). Mucormycosis was considered disseminated if
there was radiographic evidence of infection in two or more noncontiguous sites.
Histopathology. Histopathologic analysis of biopsy specimens and cytopatho-
logic analysis of fine-needle aspirate specimens were performed on formalin-
fixed paraffin-embedded samples by an anatomic pathologist at the time that the
tissue specimen was obtained. All tissue samples were fixed in 10% neutral-
buffered formalin and processed per routine protocols to paraffin blocks. The
cohort included all cases in which this initial pathological assessment suggested
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mucormycosis. All available samples were reviewed a second time by an infec-
tious disease pathologist (D.A.M.) at the time that the study was completed for
confirmation. The histological sections examined by the infectious disease pa-
thologist were the same sections analyzed at initial diagnosis by the primary
pathologist. The primary pathologists and the expert infectious disease pathol-
ogist were blinded to PCR results.
Fungal culture. Routine fungal cultures were performed on all biopsy, aspi-
rate, and autopsy specimens. In cases where tissue culture yielded growth of a
fungus, isolated pathogens were identified by standard phenotypic methods.
Confirmatory species identification of most isolates was performed using phe-
notypic methods at a national reference laboratory (Fungus Testing Laboratory,
University of Texas Health Science Center at San Antonio, San Antonio, TX).
Molecular methods. DNA extraction and seminested PCR targeting the 18S
ribosomal DNA of Mucorales, the mitochondrial DNA of Aspergillus species,
and the human beta-globulin gene (extraction control) were performed on for-
malin-fixed paraffin-embedded tissue specimens (including biopsy specimens and
cell blocks from fine-needle aspirates) as previously described (2, 9). The primers
are located within the V4 and V5 variable regions of the 18S ribosomal DNA.
The outer primers ZM1 (5-ATT ACC ATG AGC AAA TCA GA-3) and ZM2
(5-TCC GTC AAT TCC TTT AAG TTT C-3) are complementary to nucleo-
tide positions 711 to 730 and 1117 to 1096 (Rhizopus arrhizus, GenBank accession
number AF113440), respectively. Products of the seminested reaction using
primers ZM1 and ZM3 (5-CAA TCC AAG AAT TTC ACC TCT AG-3) are
175 to 177 bp long and demonstrate enough variability to reliably identify genera
but not enough to distinguish species unequivocally.
All PCR testing was performed retrospectively at the time that the study was
completed. Tissue sections used for DNA extraction and PCR amplification were
cut from the existing tissue block at the time that the study was initiated in 2010
(months to years after original collection) using a fresh sterile blade and sterile
tubes for collection and transport to the molecular lab. For each tissue specimen,
at least two extractions and PCRs were performed on each of the two 5-micro-
meter tissue slices. In cases where multiple tissue specimens were available from
the same diagnostic procedure, up to four separate samples per case were
assayed. Mucorales and Aspergillus PCR products were sequenced as previously
described (2). Investigators who performed the PCR assays and sequencing were
blinded to clinical information and tissue culture results.
Analysis. Concordance of pathological, microbiologic, and Mucorales PCR
sequencing results were assessed to determine the order and genus in cases
where cultures grew a mold of the order Mucorales. In cases where cultures did
not grow, the ability of PCR to identify the infecting mold to the genus level was
assessed. The performance characteristics of Mucorales PCR and culture were
compared by McNemar’s test. Statistical analysis was performed using SAS
(version 9.2) software (SAS Institute Incorporated, Cary, NC).
RESULTS
During the study period, proven mucormycosis was diag-
nosed in 29 patients on the basis of initial pathological review
at the time of the clinical illness. The cohort included 14
patients with hematologic malignancy and 15 HSCT recipients.
Diagnosis was made by tissue biopsy in 21 patients, fine-needle
tissue aspiration in 3 patients, and autopsy in 5 patients. There
were 12 episodes of disseminated infection and 17 episodes of
localized infection, including 9 sino-orbital infections, 6 pul-
monary infections, and 2 cutaneous infections.
Fungal tissue cultures grew Mucorales in 13 of 29 cases,
including Rhizopus spp. (n  5), Mucor spp. (n  3), Cunning-
hamella spp. (n  2), Rhizomucor spp. (n  2), and Lichtheimia
spp. (n  1). One tissue sample from a patient with sino-orbital
infection grew both Mucor circinelloides and Curvularia clavata.
Among the 13 cases where both cultures grew Mucorales
and initial review of tissue pathology was consistent with mu-
cormycosis, 12 specimens were available when the study was
performed for PCR assays and expert pathological review (Fig.
1). Ten of 12 were Mucorales PCR positive, and sequencing
results for 9 of these were concordant with culture results to
the genus level. All 12 samples were Aspergillus PCR negative,
and all 12 appeared to have infections consistent with mucor-
mycosis on expert pathological review. One case was PCR
positive for mucormycosis, but the sequencing result, Rhizomu-
cor spp., was discordant at the genus level with the culture
result, Mucor spp. The cultured fungus in this case was iden-
tified locally, but the isolated species was not sent to the ref-
FIG. 1. Results of Mucorales and Aspergillus PCR and expert pathological review. path, pathological; AspPCR, Aspergillus PCR; *, one tissue
sample each from the culture-positive and culture-negative groups was not available for pathological review and PCR at the time that the study
was undertaken; †, a cultured fungus was identified locally, but the species was not confirmed by the reference laboratory.
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erence laboratory for confirmation. Two of 12 cases in which
cultures grew Mucorales were PCR negative, including 1 case
that was also human beta-globulin PCR (control) negative.
Among the 16 cases where mucormycosis was diagnosed on
the basis of initial review of tissue histopathology alone, 15
paraffin-embedded specimens were available at the time that
the study was performed for PCR with sequencing and expert
pathological review (Fig. 1). Twelve of 15 samples were Mu-
corales PCR positive, and the findings of expert pathological
review were consistent with mucormycosis in 10 of these 12
samples. Sequencing identified the following Mucorales: Rhi-
zopus spp. (n  4), Cunninghamella spp. (n  4), Rhizomucor
spp. (n  3), and Lichtheimia spp. (n  1).
Three of 15 culture-negative cases were Mucorales PCR
negative. Two of these three were Aspergillus PCR negative;
expert pathological review of these two cases suggested mu-
cormycosis in one case, and the infection could not be iden-
tified further than an invasive mold infection in the other.
The third culture-negative Mucorales PCR-negative case
was Aspergillus PCR positive, with Aspergillus flavus identified
by sequencing. Blinded expert pathological review of this case
also suggested invasive aspergillosis.
Among the five cases in which Mucorales PCR did not
amplify, one sample each was from 2001, 2004, and 2005 and
two samples were from 2009; thus, there was no relationship
between the age of the sample and Mucorales PCR negativity.
Overall, Mucorales PCR was positive in 22 of 27 tissue
specimens that were assessed. In comparison to tissue culture,
Mucorales PCR was significantly more likely to confirm mu-
cormycosis in pathologically defined cases (P  0.008).
DISCUSSION
These data demonstrate that Mucorales PCR of formalin-
fixed paraffin-embedded tissue can be a useful tool for confir-
mation of pathological diagnosis of mucormycosis. Among 27
tissue specimens with initial histologic evidence of mucormy-
cosis, Mucorales PCR was positive in 22 specimens. Further-
more, we found a high rate of concordance among 12 speci-
mens in which tissue culture grew Mucorales: PCR confirmed
mucormycosis in 10 (83%), and the sequencing result was
concordant with the culture result at the genus level in 9
specimens. Comparison of Mucorales PCR results to those of
microbiologic culture strongly suggests the accuracy of this
technique and allowed identification of the infecting mold in
12 culture-negative cases in this cohort. The present study
confirms and extends findings from previous studies which
assessed the performance of this technique in a limited number
of cases of solely histopathologically identified mucormycosis
(2, 9) and in culture-proven cases with non-formalin-fixed
specimens (9, 10). Our data demonstrate that Mucorales PCR
with sequencing offers a reliable way to confirm tissue diagno-
sis of mucormycosis and to identify the infecting species,
thereby allowing targeted antifungal therapy.
Mucorales PCR was negative in 5 tissue specimens with
initial histopathologic evidence of mucormycosis. These nega-
tive samples included one tissue specimen that was repeatedly
Aspergillus PCR positive and that appeared to a blinded expert
pathologist to have an infection consistent with invasive
aspergillosis, suggesting that the initial pathological diagno-
sis of mucormycosis made at the time of infection may have
been incorrect. Another negative specimen was both Aspergil-
lus PCR negative and human beta-globulin (control) PCR neg-
ative, suggesting that the DNA in the specimen was destroyed
in the process of fixation, sample storage, or DNA extraction.
The remaining three Mucorales PCR-negative specimens were
control PCR positive and Aspergillus PCR negative. On expert
pathological review, the findings for one of these specimens, in
which there was limited tissue, was not characteristic for mucor-
mycosis or aspergillosis. These negative Mucorales PCR results
may be due to technical factors, such as a limited amount of
fungal DNA in small tissue specimens or degradation of fungal
DNA, particularly in the older specimens in this retrospective
study. In addition, the negative Mucorales PCR result in the case
where the infection was not characteristic for mucormycosis or
aspergillosis on expert pathological review suggests possible in-
fection due to a less common other mold (e.g., Fusarium spp.).
In summary, Mucorales PCR of formalin-fixed paraffin-em-
bedded tissue samples with sequencing had a high rate of
concordance with tissue culture to the genus level and allowed
diagnostic confirmation and species identification in 12 of 15
cases of mucormycosis diagnosed solely on the basis of histopa-
thology. This is a useful tool that can improve tissue diagnosis of
mucormycosis and characterization of culture-negative invasive
mold infection, thus facilitating targeted antifungal therapy.
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